When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
Whatever the consensus opinion may be, our team at StockStory cuts through the noise by conducting independent analysis to determine a company’s long-term prospects. Keeping that in mind, here is one stock where you should be greedy instead of fearful and two where the outlook is warranted.
Two Stocks to Sell:
Universal Logistics (ULH)
Consensus Price Target: $17 (4.6% implied return)
Founded in 1932, Universal Logistics (NASDAQ: ULH) is a provider of customized transportation and logistics solutions operating throughout the United States and in Mexico, Canada, and Colombia.
Why Do We Steer Clear of ULH?
- Products and services are facing significant end-market challenges during this cycle as sales have declined by 5.2% annually over the last two years
- Waning returns on capital imply its previous profit engines are losing steam
- Limited cash reserves may force the company to seek unfavorable financing terms that could dilute shareholders
Universal Logistics is trading at $16.26 per share, or 20.8x forward P/E. To fully understand why you should be careful with ULH, check out our full research report (it’s free).
Guardant Health (GH)
Consensus Price Target: $135.76 (6.8% implied return)
Pioneering the field of "liquid biopsy" with technology that can identify cancer-specific genetic mutations from a simple blood draw, Guardant Health (NASDAQ: GH) develops blood tests that detect and monitor cancer by analyzing tumor DNA in the bloodstream, helping doctors make treatment decisions without invasive biopsies.
Why Are We Wary of GH?
- Revenue base of $1.08 billion indicates it’s still subscale compared to its larger peers (though this creates opportunities to expand into untapped markets)
- Cash-burning tendencies make us wonder if it can sustainably generate shareholder value
- Negative earnings profile makes it challenging to secure favorable financing terms from lenders
At $127.11 per share, Guardant Health trades at 12.3x forward price-to-sales. Dive into our free research report to see why there are better opportunities than GH.
One Stock to Watch:
Humana (HUM)
Consensus Price Target: $280.50 (-14.1% implied return)
With over 80% of its revenue derived from federal government contracts, Humana (NYSE: HUM) provides health insurance plans and healthcare services to approximately 17 million members, with a strong focus on Medicare Advantage plans for seniors.
Why Does HUM Stand Out?
- Solid 13.6% annual revenue growth over the last two years indicates its offerings solve complex business issues
- Dominant market position is represented by its $137.3 billion in revenue, which gives it negotiating power over membership pricing and reimbursement rates
- Projected revenue growth of 19.4% for the next 12 months is above its two-year trend, pointing to accelerating demand
Humana’s stock price of $326.50 implies a valuation ratio of 30.5x forward P/E. Is now a good time to buy? See for yourself in our in-depth research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
